Amgen Inc.
Amgen Inc.'s announcement last week of sluggish U.S. Neupogen G-CSF sales for the quarter to date triggered a spate of analyst reappraisals on AMGN, just three weeks after lower-than-expected fourth quarter earnings sent analysts through the same exercise.